129764786804375000_65Guosen securities: medicine stocks or looking for higher growth than expected stocks (stock-pickers) focused on steady growth of the company, small Q1 base renders the company high growth more than expected growth 100%: God of weichang shutai.
Growth is expected 50-100%: huahai (main 50% above), the Sun
tera power leveling, Hanyu, Tomson times the health. Growth is expected 30-50%: tasly (main 42%), Donkey-hide gelatin (35%), Yi-Bai (45%)
Drug-Kun (45%), man Fu (35%), anti-inflammatory and analgesic bolus (30%), Dec, and haixiang
diablo 3 power leveling, Xinhua.
Growth is expected 20-30%: white drug, East China, haizheng, Heng Shui, ConMed, double Heron, 39, pientzehuang, and triumphant Po, and us, Thailand, laimei, Watson, credit balance, credit. Growth is expected 0-20%:Consistent, guoyao, Hong margin, Tong ren Tang, mayinglong, sentient beings, Ling, Rachel, and double cranes, Xinhe, conom, Dyan, laishi, Kyushu pass, the Cape, and diving.
Expected to decline: Hua LAN, Temple of heaven, and Zhejiang medicine, conba
diablo 3 gold, Kang Zhi, apply medicationto.
Tip: have not been concluded in the first quarter, above based on the company's business trends and forecast judgments, for reference. Investment advicePharmaceutical stocks valued, deterministic quality now pharmaceutical sector adjustment for the growth of a more adequate, reasonable valuations (focus company 11-12PE25x, 20x), with the policy of disturbance factors and gradually weakened, absolute gains. Proposal focuses on developing strategic clarity, a subdivision of clear performance trends leading companies: tasly, Dong-e e-Jiao, YunnanBaiyao Fu medicine, Eastern medicine, people, ConMed drug industry, hisun pharmaceutical industry, hengrui medicine, guoyao consistent; concerns 1 quarterly growth in fast company: Yi Bai pharmaceuticals, Kunming pharmaceutical, and underestimate the value and return of growth companies: CR 39, permanent groups, in three refined drugs. (Guosen Securities Research Institute) online statement Gold: Gold-line reproduced above, notThat confirmed that the description for investor use only and does not constitute investment advice. Investor operations accordingly, at your own risk.
Others:
No comments:
Post a Comment